Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer
Advanced ovarian cancer is the leading non-breast gynaecologic cause of malignant pleural effusion. Aim of this study was to assess the efficacy of mitoxantrone sclerotherapy as a palliative treatment of malignant pleural effusions due to ovarian cancer.
Sixty women with known ovarian cancer and malignant recurrent symptomatic pleural effusion were treated with chest tube drainage followed by intrapleural mitoxantrone sclerotherapy. Survival, complications and response to pleurodesis were recorded. The data are expressed as the mean ± SEM and the median.
The mean age of the entire group was 64 ± 11,24 years. The mean interval between diagnosis of ovarian cancer and presentation of the effusion was 10 ± 2,1 months. Eighteen patients (30%) had pleural effusion as the first evidence of recurrence. The mean volume of effusion drained was 1050 ± 105 ml and chest tube was removed within 4 days in 75% of patients. There were no deaths related to the procedure. Side effects of chemical pleurodesis included fever (37–38,5°C) chest pain, nausea and vomiting. At 30 days among 60 treated effusions, there was an 88% overall response rate, including 41 complete responses and 12 partial responses. At 60 days the overall response was 80% (38 complete responses and 10 partial responses). The mean survival of the entire population was 7,5 ± 1,2 months.
Mitoxantrone is effective in the treatment of malignant pleural effusion secondary to ovarian cancer without causing significant local or systemic toxicity.
- Hausheer FH, Yarbro JW: Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985, 12:54–75.
- Lynch TJ: Management of malignant pleural effusions. Chest 1993, 103:385–389.
- Saffran L, Ost D, Fein A, Schiff M: Outpatient pleurodesis of malignant pleural effusions using a small-bore pig tail catheter. Chest 2000, 118:417–421. CrossRef
- Dvoretsky PM, Richards KA, Bonfiglio TA: The pathology and behavior of ovarian cancer. Path Ann 1989, 24:1–24.
- Ovary In American Joint Committee on Cancer: AJCC Cancer Staging Manual 6 Edition New York, NY: Springer 2002, 275–284.
- Statement of the American Thoracic Society: management of malignant pleural effusions Am J Respir Crit Care Med 2000, 162:1987–2001.
- Sahn SA: Pleural effusion in lung cancer. Clin Chest Med 1993, 14:189–2000.
- Johnston WW: The malignant pleural effusion: a review of cytopathologic diagnosis of 584 specimens from 472 consecutive patients. Cancer 1985, 56:905–909. CrossRef
- Antunes G, Neville E, Duffy J, Ali N: BTS guidelines for the management of malignant pleural effusions. Thorax 2003, 58:29–38. CrossRef
- Hausheer FH, Yarbro JW: Diagnosis and treatment of malignant pleural effusion. Cancer Metastasis Rev 1987, 6:23–40. CrossRef
- Patz E, McAdams P, Erasmus J, Goodman P, Culhane D, Gilkeson R, Herndon J: Sclerotherapy for malignant pleural effusions. A prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998, 113:1305–1311. CrossRef
- Seaton KG, Patz EF Jr, Goodman PC: Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. Am J Roentgen 1995, 164:589–591.
- Cheng D, Chan YM, Ng T, Cheung A, Ngan H, Wong LC: Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynaecological cancer. Acta Obstet Gynecol Scand 1999, 443–446.
- Hartman DL, Gaither JM, Kesler KA: Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993, 105:743–748.
- Gravelyn TR, Michelson MK, Gross BH: Tetracycline pleurodesis for malignant pleural effusions: a 10-year retrospective study. Cancer 1987, 59:1973–1977. CrossRef
- Goff BA, Mueller PR, Muntz HG: Small chest tube drainage followed by bleomycin sclerosis for malignant pleural effusions. Obstet Gynecol 1993, 81:993–996.
- Moffet MJ, Ruckdeschel JC: Bleomycin and tetracycline in malignant pleural effusions: a review. Semin Oncol 1992, 19:59–63.
- Ostrowski MJ: Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions. J Surg Oncol 1989, 1:7–13. CrossRef
- Ruckdeschel JC, Moores D, Lee JY, Einhorn LH, Momdelbaum I, Koeller J, Weiss GR, Losada M, Koller JH: Intrapleural therapy for malignant pleural effusions: a randomised comparison of bleomycin and tetracycline. Chest 1991,100(6):1528–1535. CrossRef
- Rehse DH, Aye RW, Florence MG: Respiratory failure following talc pleurodesis. Am J Surg 1999, 177:437–440. CrossRef
- Marom EM, Patz EF, Erasmus JJ, McAdams HP, Goodman PC, Herndon JE: Malignant pleural effusions: treatment with small-bore catheter thoracostomy and talc pleurodesis. Radiology 1999, 210:277–281.
- Fingar BL: Sclerosing agents used to control malignant pleural effusions. Hosp Pharm 1992, 27:622–628.
- Vargas FS, Teixeira LR, Antonangelo L, Silva lM, Strauz CM, Light RW: Acute and chronic pleural changes after intrapleural instillation of mitoxantrone in rabbits. Lung 1998, 176:227–236. CrossRef
- Seitzer D, Musch E, Kuhn W: Die locale behandlung maligner pleuraergusse bei gynakologischen tumoren. Zent Bl Gynakol 1990, 112:757–765.
- Musch E, Loos U, Mackes KG: Intrapleural mitoxantrone in the treatment of malignant pleural effusions. In Advances in Regional Cancer Therapy 1 Edition (Edited by: Kreidler H, Link KH, Aigner RB). Basel: Karger 1988, 184–189.
- Maiche AG, Virkunnen P, Kontkanen T, Mokkynen K, Porkka K: Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. Am J Clin Oncol 1993, 16:50–53. CrossRef
- Van Belle AF, Velde GPM, Weuters EFM: Chemical pleurodesis with mitoxantrone in the management of malignant effusion. Eur J Cancer 1998, 34:206–207. CrossRef
- Morales M, Exposito MC: Intrapleural mitoxantrone for the palliative care treatment of malignant pleural effusions. Support Care Cancer 1995, 3:147–149. CrossRef
- Groth G, Gatzmeier U, Haussingen K, Heckmayr M, Magnussen H, Neuhauss R, Pavel JV: Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 1991, 2:213–215.
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-684X/3/4/prepub
- Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
BMC Palliative Care
- Online Date
- September 2004
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 1. Cardiothoracic Surgery Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece
- 2. Anaesthesiology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece
- 3. Gynaecologic Oncology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece
- 4. Cytopathology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece